Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by Xwing229on Sep 28, 2020 8:45am
163 Views
Post# 31628031

News additional info sent by GA

News additional info sent by GADear Friend:
 
Attached is a NR which has been released at 7:00 am (Eastern).
 
Here is some background:
 
1. This is the first VMS+3.0 we have installed in Europe (we have done 4 in Canada by traveling to the site).  We are very pleased it has gone into the number one hospital in Europe in Rotterdam.
2. The cardiologist will immediately use it for routine clinical cases to address children and adults.
3. We must emphasize that we shipped the unit to the hospital and installed it remotely with minimal assistance for the hospital staff.  This validates our new approach which is a major cost savings as well as time savings for the Company.  It also lowers the barrier for adoption as IT departments at hospitals are overworked and slow to schedule installations, which require on-site interactions.
4. Installation means hooking it up to their internal archive system as well as calibrating it to a number fo ultrasound machines and probes so it can be used throughout the department.
5. They also received a reviewing station so they can internally review cases in a viewing room to allow more cases to be scanned using the VMS+3.0, while previous cases are being analyzed.
6. The cardiology team at Erasmus is well respected in Europe and once they have sufficient experience using the VMS+3.0 is expected to recommend other centers should be using it to better evaluate their patients
 
Friday was an amazing day for shareholders with over 19M shares traded (28% of float) on all exchanges at a weighted average price of $.097.  The stock is now in stronger hands and this is a new base for the Company.  We are making excellent progress in the marketplace as today”s news release demonstrates.
 
Thank you for your continued support.

Regards,
 
Dr. George Adams ICD.D
 

<< Previous
Bullboard Posts
Next >>